Substance Use Disorders
Substance use disorders (SUDs), particularly opioid use disorder and alcohol use disorder, are chronic, relapsing conditions that remain major public health challenges with significant unmet medical need. Individuals with opioid and alcohol use disorders frequently experience cycles of withdrawal, craving, agitation, and relapse, driven in part by neurobiological changes in stress, reward, and inflammatory signaling pathways.
Emerging evidence suggests that dysregulated lipid signaling and oxidative stress contribute to neural circuit dysfunction associated with substance dependence and behavioral instability. Through inhibition of ALOX15, Kinoxis is targeting disease-relevant pathways that modulate neural activity and behavioral responses, with the goal of reducing withdrawal-related agitation, stabilizing brain function, and supporting recovery for individuals living with opioid and alcohol use disorders.
Alcohol Use Disorder
Alcohol is the most used psychoactive substance globally, and alcohol use disorder is one of the most prevalent substance use disorders.1
In 2019, 400 million people aged 15 and older were living with alcohol use disorder and alcohol contributed to 2.9 million deaths.2 These alarming statistics underscore the widespread and dangerous impact of alcohol use, which not only affects individual health but also places a heavy burden on healthcare systems and society as a whole.
In preclinical studies, KNX100 has shown potential for treating alcohol use disorder (AUD). In collaboration with the National Institute on Alcohol Abuse and Alcoholism (NIAAA), KNX100 is progressing toward a Phase 1b alcohol interaction studies, followed by a Phase 2a proof-of-concept study focused on reducing craving.
Opioid Use Disorder
Treating opioid addiction is challenging and many patients who enter recovery will relapse.
The ongoing opioid crisis places a heavy burden on individuals and families, underscoring the urgent need for comprehensive treatment programs and long-term support to improve outcomes for those battling OUD.
In preclinical studies, KNX100 showed potential to treat the negative emotional symptoms of opioid withdrawal and to reduce opioid craving by normalising activity in a highly disease relevant brain circuit that is altered in opioid use disorder. Kinoxis have been working closing with the US NIH to develop KNX100 for the treatment of opioid use disorder. Kinoxis are advancing KNX100 for the treatment of craving and the negative affective symptoms of opioid use disorder
Methamphetamine Use Disorder
There are no approved medications for treating methamphetamine or any stimulant use disorder.
With 1.6 million people in the USA alone suffering from methamphetamine use disorder, and fewer than one-third receiving any treatment1,2, there is a desperate need for novel therapeutic interventions. The time to change the lives of these patients and their families is now.
In preclinical studies, KNX100 has shown potential to treat methamphetamine and other stimulant use disorders. Kinoxis is advancing KNX100 as a treatment for methamphetamine use disorder with a planned Phase 1b/2a study targeting methamphetamine craving.
Find out about our latest clinical trials
© Kinoxis Therapeutics | All Rights Reserved | Website by Graphink Design and Integrale Marketing